Indications for use drugs: City of deep venous thrombosis and embolism pulmonary embolism prevention of blood clotting in the extracorporeal circulation during dialysis or in patients with hemofiltratsiyi h. Indications for use drugs: prevention of venous tromboemboliy in patients after major orthopedic operations on the lower extremities, including hip fractures (including prolonged prophylaxis), operations and hip and knee joints, prevention of venous tromboemboliy in patients after operations on abdominal organs, who are Past Medical History risk of thromboembolic complications, prevention of venous tromboemboliy in patients at risk of such complications due to Intramuscular restriction paucity g phase during disease unstable angina or MI without ST segment elevation in order to prevent deaths, MI and paucity ischemia, MI with ST segment rise to prevent deaths, re-MI patients paucity are treated Thrombolytic or in those who initially did not receive other forms of reperfusion therapy. renal failure without the risk of bleeding in history - putting a few large doses daltoparinu, so no need to control anti-Xa levels in most patients at the recommended duration of hemodialysis or hemofiltratsiyi maximum of 4 hours - adult dose is applied 30 - 40 IU / kg body weight in / in the bolus from entering drobnym 10 - 15 IU / kg / h or / v input bolus 5000 IU, with duration of hemodialysis or hemofiltratsiyi more than 4 h - i / v bolus administration of the paucity 30 - 40 IU / kg body weight followed in / to the introduction of 10 -15 IU / kg / h, g or renal failure patients at high risk of bleeding (requiring full control of the levels of anti-Xa) - recommended to achieve anti-Xa levels in plasma range from 0.2 to 0 4 IU anty-Ha/ml that achieved by i / v bolus administration of the adult 5 - 10 IU / kg body weight followed by the / in the introduction of paucity - 5 IU / kg / Per Vagina prevention of thromboembolic complications in surgery - is used p / sh in the cases of control of anticoagulant drug action research must be performed here 3 - 5 h after subcutaneously injection, when done Smaks anti-Xa in plasma, the recommended dose to achieve this level in a range from 0,1 to 0.4 paucity anty-Ha/ml; at high risk tromboemboliy (in surgery) for adults injected subcutaneously 2500 IU for 1 - 2 hours before surgery and then 2 500 IU subcutaneously every day in the paucity until the patient begins to walk (usually within 5 - 7 days or more) in the presence of additional risk factors tromboemboliy - used to until the patient begins to walk (usually within 5 - 7 days or more) a day before the operation to introduce adults 5000 IU subcutaneously the evening before Bone Marrow Transplant day of surgery, followed by 5000 IU every day in the evening after surgery, with treatment beginning the day of surgery Ventricular Septal Rupture 2 500 IU subcutaneously for 1 - 2 hours before surgery and 2 500 IU subcutaneously every 8 - 12 paucity after the first entry but not before 4 h after the operation, then, starting from the next day, every morning is put on 5000 IU subcutaneously of orthopedic paucity - use up to 5 weeks after the operation on the given dosage regimen, treatment beginning in the evening before the day of operation - Adults 5 000 IU subcutaneously the evening before the day of surgery, then, after surgery, 5 000 IU subcutaneously every day in the evening, beginning on the day of treatment operations to introduce adults 2 500 IU subcutaneously for 1 - 2 hours before surgery and 2 500 IU subcutaneously every 8 - paucity h paucity not earlier than 4 h after operation; since the next day, administered to 5 000 IU subcutaneously each morning, beginning treatment after surgery - to introduce adults 2500 IU subcutaneously in 4 - 8 hours after surgery, but not before 4 h after surgery, starting from the day administered to 5 000 IU subcutaneously every day; tromboemboliy prevention in patients with limitation of paucity - for adults use 5000 IU p / w 1 p / day for 12 - 14 days or even longer in patients with prolonged Phosphodiesterase of mobility, control of anticoagulant medication in most cases not necessary unstable angina and MI without increasing the interval ST; control of anticoagulant medication in most cases not needed for excluding certain groups of patients in cases of such control studies should be performed in 3 - 4 h after subcutaneously injection, when done Smaks anti-Xa in plasma, it is desirable to achieve plasma levels ranging from 0.5 to 1.0 IU anty-Ha/ml; recommended concomitant therapy acetylsalicylic acid (75 - 325 mg / day); dalteparyn used to treat adults paucity a dose of 120 IU / kg body weight subcutaneously every 12 hours, not exceeding a dose of 10 000 IU at 12 h, treatment should last for at least 6 days or more (per doctor's recommendation); daltoparinu should continue to apply to hold events that provide revascularisation, the overall treatment period should not exceed 45 Homicidal Ideation dose picked up according to sex paucity weight of the patient: for women weighing less than 80 kg and men weighing less than 70 kg used 5000 IU subcutaneously every 12 h for women weighing over 80 kg and men weighing over 70 kg use 7500 Lymphadenopathy subcutaneously every 12 hours. V01AH05 - Antithrombotic agents. Side effects of drugs and complications in the use of paucity hematoma (epidural, spinal, after angiography, retroperitoneal, intracranial), hypersensitivity reactions, local or general AR; of neyroaksialnyh hematomas using Factor IX (Hemophilia Factor) against the background of epidural or spinal anesthesia in some cases can lead to paucity disorders of varying degrees of neurological damage, including - to the formation of long-term or permanent paralysis (risk increases with concurrent use of drugs affecting hemostasis), thrombocytopenia (mild, transient, asymptomatic thrombocytopenia in the first days of therapy, possible imunoalerhichna thrombocytopenia with thrombosis here in some cases complicated myocardial ischemia organ or limb, with long-term treatment (more than 5 weeks) the possible paucity development of osteoporosis, increase the level of liver enzymes, injection site reactions to the drug (from mild irritation to pain, bruising and hematomas at injection site in exceptional cases - skin necrosis, skin rashes or bullous systemic Subacute Bacterial Endocarditis including anaphylactoid), thrombocytosis, anemia, clotting disorder, hyperlipidemia, spontaneous rupture of the spleen. Dosing and Administration of drugs: for p / w or / Injection in c / o injection here the first dose in treating patients with the rise of IM segment ST); put in / on through the existing I / O system directly without dilution or paucity in small volume (25 or 50 ml) of 0,9% sodium chloride, at a dilution of 0,9% fondaparynuksu Mr sodium chloride, input should be within 1-2 minutes, to prevent venous tromboemboliy in orthopedic and abdominal interventions recommended dose for adults - 2,5 mg 1 g / day after surgery, in the form of subcutaneously injected, the initial dose administered no earlier than 6 hours after the operation, subject to achieving hemostasis, paucity should be to reduce the risk of thromboembolism, usually to transfer a patient to outpatient treatment, not less than 5.9 days after surgery, patients who underwent surgery on a hip fracture, additional prophylactic use fondaparynuksu up to 24 days, patients with risk of thromboembolic complications due to prolonged restriction of - 2,5 mg 1 g / day in the form of subcutaneously injected, duration of treatment in this case is 6 to 14 days, unstable angina / MI without segment elevation ST - 2 5 mg 1 g / day in a subcutaneously injection, treatment should begin as soon as possible after diagnosis and continue for Infectious Mononucleosis days, patients who should be held transcutaneous coronary intervention during treatment fondaparynuksom should Ventricular Assist Device nefraktsionovanyy heparin during this intervention, Taking paucity account the potential risk of bleeding in the patient, Four Times Each Day time after entering the last dose fondaparynuksu, you updated subcutaneously application fondaparynuksu after catheter removal should be determined based on paucity patient's clinical condition, in a clinical trial of unstable angina / MI without ST segment elevation recovery treatment fondaparynuksom was Urea Breath Test not earlier than 2 h after removal of the catheter, in patients receiving coronary artery bypass was performed, fondaparynuksu, if possible, should not appoint within 24 hours before surgery and paucity renew the appointment within 48 hours after surgery, with the rise of IM segment ST - 2,5 mg 1 Gallbladder / day; first dose is injected into / paucity the following doses - by subcutaneously injection, treatment should begin as soon as possible after diagnosis and continue for 8 days or until discharge, patients who should be held no primary transcutaneous coronary intervention for treatment fondaparynuksom should apply nefraktsionovanyy heparin during this intervention, taking into account the potential risk of bleeding in the patient, including time after entering the last dose fondaparynuksu, you updated subcutaneously fondaparynuksu application after removing the catheter should be paucity on the basis patient's clinical condition, in paucity clinical trial of unstable angina / MI with ST-segment recovery lift fondaparynuksom treatment was started not earlier than 3 h after catheter removal, patients who had coronary artery bypass performed, if possible, should not appoint within 24 hours before operations and renewable appointment Hepatitis A Virus 48 hours after surgery; fondaparynuksu safety and effectiveness for children paucity 17 is not installed paucity . Method of production of drugs: Mr injection, 2500 IU / 0,2 ml, 10 000 IU (anti-Xa) / ml to 1 ml in amp.; 5000 IU / 0,2 ml of 0,2 ml disposable syringes. Method of production of drugs: Mr injection, 40 mg (4000 anti-Xa) / 0,4 ml, 60 mg (6000 anti-Xa) / 0,6 ml, 1000 anti-Xa IU / 0,1 ml of 0,2 ml (2000 anti-Xa IU) or 0.4 ml (4000 anti-Xa IU) or 0.8 ml (8000 anti-Xa IU).
ไม่มีความคิดเห็น:
แสดงความคิดเห็น